fulvestrant
| Price | $1 |
| Package | 1g |
| Min. Order: | 1g |
| Supply Ability: | 100 Kilogram/Kilograms per Month |
| Update Time: | 2019-08-02 |
Product Details
| Product Name: fulvestrant | CAS No.: 129453-61-8 |
| Min. Order: 1g | Purity: 99% |
| Supply Ability: 100 Kilogram/Kilograms per Month | Release date: 2019/08/02 |
MF: C32H47F5O3S
MW: 606.77
mp 104-106°C
storage temp. 2-8°C
Chemical Properties White Powder
Usage A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
Usage Antiestrogen
Biological Activity A high affinity estrogen receptor antagonist (IC 50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Nuclear Receptors;Chiral Reagents;Steroids;Sulfur & Selenium Compounds;FASLODEX;Anti-cancer&immunity
Synonyms: ICI 182,780;;-13C1-D2;FASLODEX;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;7A,17B-[9[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL;(7alpha,17beta)-nonyl);estra-1,3,5(10)-triene-3,17-diol,7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)
Description:
Fulvestrant Acetate (trade name Faslodex, by Astra Zeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.
Description:
Fulvestrant Acetate (trade name Faslodex, by Astra Zeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/1kg |
VIP1Y
|
hebei hongtan Biotechnology Co., Ltd
|
2024-05-14 | |
| $10.00/1kg |
VIP1Y
|
Nantong Guangyuan Chemicl Co,Ltd
|
2023-11-01 | |
| $50.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-08-02 | ||
| $0.00/25KG |
VIP2Y
|
shandong perfect biotechnology co.ltd
|
2023-07-07 | |
| $0.00/1g |
Hebei Bonster Technology Co.,Limited
|
2022-11-04 | ||
| $10.00/1KG |
Shijiazhuang tongyang Import and Export Co., LTD
|
2021-08-12 | ||
| $0.00/1g |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-07-16 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-09 | ||
| $795.00/10g/Bag |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-02 | |
| $10.00/1KG |
Wuhan Monad Medicine Tech Co.,LTD
|
2021-04-20 |
China- Since: 2014-05-13
- Address: Room 2004, Oriental Century Square Tower A, East Road Yellow River, Xinhua District, Cangzhou City
INQUIRY